Market Place
Sourcing Support
Kardigan Hypertension Drug Tangles Biomarker Win With BP Miss
30 Mar 2026 //
FIERCE BIOTECH
Ionis Slashes Tryngolza`s Price Ahead Of Planned Label Expansion
25 Mar 2026 //
FIERCE PHARMA
Ionis NDA For Zilganersen Gets FDA Priority Review
23 Mar 2026 //
BUSINESSWIRE
Ionis To Present New Data On DAWNZERA In Hereditary Angioedema
27 Feb 2026 //
BUSINESSWIRE
FDA Grants Priority Review to Olezarsen sNDA for Severe HTG
26 Feb 2026 //
BUSINESSWIRE
Ionis Doubles Its Sales Projection for Tryngolza in sHTG to $2B
13 Jan 2026 //
FIERCE PHARMA
Ionis Set for 2026 Momentum: Two Launches, Key Wins
12 Jan 2026 //
BUSINESSWIRE
GSK & Ionis`s `Functional Cure` For Hep B Proves Worth In Ph. 3
07 Jan 2026 //
BUSINESSWIRE
Deciphera Presents Positive Phase 2A Sapablursen Results
06 Dec 2025 //
BUSINESSWIRE
Metagenomi To Present Preclinical Data On APOC3 Collaboration
01 Dec 2025 //
GLOBENEWSWIRE
Ionis` Olezarsen Gets FDA Breakthrough Tag for sHTG
01 Dec 2025 //
BUSINESSWIRE
Lilly, Otsuka & More Earn Nods From Europe`s CHMP
14 Nov 2025 //
FIERCE PHARMA
Ionis Advances Tryngolza to Cut Triglyceride, Case for FDA Filing
10 Nov 2025 //
BIOSPACE
Olezarsen Study On Severe Hypertriglyceridemia Revealed at AHA
08 Nov 2025 //
BUSINESSWIRE
CORE, CORE2 Data on Olezarsen for sHTG to Debut at AHA 2025
27 Oct 2025 //
BUSINESSWIRE
Ionis CEO Brett P. Monia Honored With 2025 Lifetime Achievement
21 Oct 2025 //
BUSINESSWIRE
Ionis, Arrowhead in Patent Lawsuits Over Genetic Disorder Drug
11 Sep 2025 //
REUTERS
Ionis, Biogen Advance Salanersen Into SMA Registrational Trials
25 Jun 2025 //
BUSINESSWIRE
Ionis, Sobi expand partnership for olezarsen outside US
26 Mar 2025 //
BUSINESSWIRE
Ionis To Launch Multiple Products As Commercial Biotech In 2025
13 Jan 2025 //
PR NEWSWIRE
Theratech Signs Agreement with Ionis for Olezarsen in Canada
04 Dec 2024 //
GLOBENEWSWIRE
Ionis FDA Accepts NDA for Donidalorsen in HAE Prophylaxis
04 Nov 2024 //
PR NEWSWIRE
Wainzua Recommended For EU Approval For Hereditary Amyloidosis
21 Oct 2024 //
PR NEWSWIRE
Ionis To Webcast HALOS Study Results For ION582 In Angelman Syndrome
08 Jul 2024 //
PR NEWSWIRE
GSK acquires oligonucleotide drug startup Elsie
07 Jun 2024 //
BIOPHARMADIVE
Ionis Announces Positive ION582 Angelman Syndrome Topline Results
16 May 2024 //
PR NEWSWIRE
Ionis, Biogen Announce ALS Drug Topline Phase 1/2 Results
16 May 2024 //
PR NEWSWIRE
Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen
07 Apr 2024 //
PR NEWSWIRE
Ionis to Hold Olezarsen Phase 3 Data Webcast
28 Mar 2024 //
PR NEWSWIRE
Positive olezarsen Ph 3 data to be presented at ACC 2024 meeting
25 Mar 2024 //
PR NEWSWIRE
Eplontersen granted U.S. FDA Fast Track designation for patients with ATTR-CM
08 Feb 2024 //
PRESS RELEASE
Ionis shares positive update from ongoing trial of ION582 for Angelman syndrome
11 Nov 2023 //
PR NEWSWIRE
Eplontersen Phase 3 results published in JAMA show sustained benefit
28 Sep 2023 //
PRESS RELEASE
Ionis expands eplontersen agreement with AstraZeneca
28 Jul 2023 //
PR NEWSWIRE
New data highlight potential benefit of SPINRAZA® (nusinersen)
30 Jun 2023 //
PR NEWSWIRE
Eplontersen halted ATTRv-PN disease progression
24 Apr 2023 //
PR NEWSWIRE
Ionis to present at upcoming investor conferences
28 Mar 2023 //
PRESS RELEASE
Ionis reports positive topline 66-week results of eplontersen Phase 3 study
27 Mar 2023 //
PR NEWSWIRE
Ionis accounces FDA advisory committee voted unanimously for SOD1-ALS
22 Mar 2023 //
PR NEWSWIRE
Ionis announces FDA acceptance of New Drug Application for eplontersen
08 Mar 2023 //
PR NEWSWIRE
Ionis announces GSK has advanced bepirovirsen into Phase 3 development
02 Feb 2023 //
PR NEWSWIRE
Royalty Pharma Acquires Ionis` Royalty In Spinraza, Pelacarsen For $1.1 Bln
10 Jan 2023 //
PR NEWSWIRE
